New immune cell therapy tested for Tough-to-Treat prostate cancer
NCT ID NCT06056791
Summary
This early-stage study tested a new cell therapy called INKmune in men with advanced prostate cancer that had spread and stopped responding to standard hormone treatments. The main goals were to find the safest and most effective dose and to see how well patients tolerated the treatment. Twelve men received three infusions of the therapy over several weeks while researchers monitored their safety and early signs of how the cancer responded.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carl & Edyth Lindner Center for Research and Education at The Christ Hospital and The Christ Hospital Cancer Center
Cincinnati, Ohio, 45219, United States
-
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89169, United States
-
NEXT Virginia
Fairfax, Virginia, 22031, United States
-
Renovatio Clinical
El Paso, Texas, 79915, United States
-
Renovatio Clinical
The Woodlands, Texas, 77380, United States
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
VA Greater Los Angeles Healthcare System
Los Angeles, California, 90073, United States
-
VA Puget Sound Health Care System
Seattle, Washington, 98108, United States
Conditions
Explore the condition pages connected to this study.